Last reviewed · How we verify
Tibulizumab Dose A
At a glance
| Generic name | Tibulizumab Dose A |
|---|---|
| Sponsor | Zura Bio Inc |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (PHASE2)
- BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tibulizumab Dose A CI brief — competitive landscape report
- Tibulizumab Dose A updates RSS · CI watch RSS
- Zura Bio Inc portfolio CI